A Phase 4 interventional study of voriconazole in Prophylaxis Of Invasive Fungal Infections, sponsored by Pfizer. Completed at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-06.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Invasive Fungal Infections with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Invasive Fungal Infections · France.
Among the 22 studies in Invasive Fungal Infections with a site in France, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2005, is the only one in phase 4, and was the 1st registered.
136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.
Browse Invasive Fungal Infections studies →3 of the 22 studies in Invasive Fungal Infections with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 3–64 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 70 across 67 interventional studies indexed under Invasive Fungal Infections.
Median enrollment 214 across the 14 interventional studies, 117 across the 8 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Invasive Fungal Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Invasive Fungal Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06285188Assistance Publique - Hôpitaux de ParisImmunomonitoring of Mold Invasive Infections | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Invasive Fungal Infections with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: voriconazole
Voriconazole is given to patients at least 48 hours after chemotherapy
Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 12-month follow up
Time frame: 12 months
Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 6-month Follow-up Visit
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 6-month follow up
Time frame: 6 months
Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Voriconazole Prophylaxis Until End of Prophylaxis Visit
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until the End of Prophylaxis visit
Time frame: 150 days
Time to Occurrence of Proven or Probable Invasive Fungal Infection (IFI)
Time to occurrence of proven or probable IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI since the exact day on which the IFI began will not be known.
Time frame: 12 months
Time to Occurrence of Proven or Probable New (New Pathogen) Invasive Fungal Infection (IFI)
Time to occurrence of proven or probable new (new pathogen) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI.
Time frame: 12 months
Time to Occurrence of Proven or Probable Recurrent Invasive Fungal Infection (IFI) (Same Pathogen as Previous Baseline IFI)
Time to occurrence of proven or probable recurrent (same pathogen as baseline) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI. The pathogen identified as the positive culture recorded nearest to, but not after, the proven or probable IFI, was assumed to be responsible for the IFI.
Time frame: 12 months
Survival Without Proven or Probable Invasive Fungal Infection (IFI)
Number of participants who survive (ie., are alive) without proven or probable IFI at each of the 6 and 12 month follow-up visits
Time frame: 6 months, 12 months
| Milestone | Voriconazole |
|---|---|
| Started | 45 |
| Completed | 29 |
| Not completed | 16 |
| Withdrew: Death | 11 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 12-month follow up
| participants | Voriconazole |
|---|---|
| Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit | 3 |
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 6-month follow up
| participants | Voriconazole |
|---|---|
| Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 6-month Follow-up Visit | 3 |
Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until the End of Prophylaxis visit
| participants | Voriconazole |
|---|---|
| Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Voriconazole Prophylaxis Until End of Prophylaxis Visit | 3 |
Time to occurrence of proven or probable IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI since the exact day on which the IFI began will not be known.
| days | Voriconazole |
|---|---|
| time to recurrent IFI (first subject) | 6 |
| time to recurrent IFI (second subject) | 22 |
| time to recurrent IFI (third subject) | 81 |
Time to occurrence of proven or probable new (new pathogen) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI.
| days | Voriconazole |
|---|---|
| Time to Occurrence of Proven or Probable New (New Pathogen) Invasive Fungal Infection (IFI) | 81 |
Time to occurrence of proven or probable recurrent (same pathogen as baseline) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI. The pathogen identified as the positive culture recorded nearest to, but not after, the proven or probable IFI, was assumed to be responsible for the IFI.
| days | Voriconazole |
|---|---|
| time to IFI (first subject) | 6 |
| time to IFI (second subject) | 22 |
Number of participants who survive (ie., are alive) without proven or probable IFI at each of the 6 and 12 month follow-up visits
| participants | Voriconazole |
|---|---|
| survived free of IFI until 6 months | 31 |
| survived free of IFI until 12 months | 27 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole | — | 23/45 (51.1%) | 42/45 (93.3%) |
| Event | Voriconazole |
|---|---|
| VomitingGastrointestinal disorders | 3/45 |
| DiarrhoeaGastrointestinal disorders | 2/45 |
| Graft versus host diseaseImmune system disorders | 2/45 |
| HepatotoxicityHepatobiliary disorders | 2/45 |
| PyrexiaGeneral disorders | 2/45 |
| SepsisInfections and infestations | 2/45 |
| Abdominal painGastrointestinal disorders | 1/45 |
| Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/45 |
| Atrial fibrillationCardiac disorders | 1/45 |
| Blood creatine increasedInvestigations | 1/45 |
| Event | Voriconazole |
|---|---|
| Mucosal inflammationGeneral disorders | 17/45 |
| DiarrhoeaGastrointestinal disorders | 15/45 |
| HeadacheNervous system disorders | 13/45 |
| PyrexiaGeneral disorders | 13/45 |
| VomitingGastrointestinal disorders | 13/45 |
| Graft versus host diseaseImmune system disorders | 12/45 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/45 |
| HypertensionVascular disorders | 8/45 |
| Abdominal painGastrointestinal disorders | 7/45 |
| AnaemiaBlood and lymphatic system disorders | 7/45 |
| Age Continuous(years) | Voriconazole |
|---|---|
| Mean | 48.4 ± 14.1 |
| Sex: Female, Male(Participants) | Voriconazole |
|---|---|
| Female | 17 |
| Male | 28 |
The record gives a start of Feb 2005, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole